Abstract
Chronic hepatitis C virus infection remains a significant public health problem with an estimated of 58 million people globally infected. Direct-Acting Antivirals (DAAs) have revolutionized Hepatitis C treatment and can achieve high cure rates (>90%). However, the costs of DAAs in Vietnam remain a potential barrier for treatment. Our study aims to investigate the costs of DAAs treatment for Hepatitis C in Vietnam in order to provide suggestions to increase the coverage of DAAs treatment.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
